Respimat

Respimat, or commonly referred to as Respimat SMI, with the SMI acronym to mean, Soft Mist Inhaler.

Respimat SMI is an advanced drug delivery device in comparison to MDIs or DPIs used for the treatment of Asthma, COPD, and other respiratory conditions.

Its developer, Boehringer Ingelheim, is currently conducting Phase III clinical trials in the US with a variety of their products, such as Spiriva and Combivent.